BIO 2015 Dispatches: Acorda CEO Cohen To Bring 'Passion' To BIO Chairmanship
This article was originally published in The Pink Sheet Daily
Executive Summary
Congenial Acorda CEO Ron Cohen is chosen to lead the industry group during the upcoming year as the biotech industry gathers in Philadelphia for BIO's annual conference.
You may also be interested in...
Ampyra Approval: Acorda's Lessons Learned
There are many factors that contributed to Acorda's success in gaining approval for Ampyra (dalfampridine), but looking back at the process, CEO Ron Cohen and Chief Scientific Officer Andy Blight agree that the biggest asset was having a Special Protocol Assessment for the Phase III trials.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.